Agios Pharmaceuticals (STU:8AP) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8AP Agios Pharmaceuticals Inc STU:8AP
53 GF Score
Price €34.80
GF Value €74.31
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Agios Pharmaceuticals Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:8AP
53GF Score
Agios Pharmaceuticals Inc STU:8AP
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Agios Pharmaceuticals (STU:8AP) Overvalued in 2026?

Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued. The current stock price of €34.80 is trading 53.2% below its estimated GF Value™ of €74.31. GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.

Key valuation signals for STU:8AP:

  • Dividends Received:
  • GF Value™: €74.31 vs. price of €34.80 (53.2% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the STU:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Agios Pharmaceuticals Business Description

Other Exchanges AGIO:USA0HB0:UK
Address 88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
53GF Score

Get the complete analysis for STU:8AP

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.80
Price
€74.31
GF Value